Improving detection and treatment of drug resistance in cancers
Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations
This study is looking at how some genetic changes can make certain cancers, like melanoma, resistant to treatment, and it aims to find these changes in patients before they start therapy so that doctors can tailor better treatment plans to help improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10684107 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain genetic mutations can lead to drug resistance in various diseases, particularly cancers like melanoma. By using advanced DNA mutation detection technology, the study aims to identify pre-existing subclonal drug resistance mutations in patient samples before treatment begins. The researchers will also utilize mouse models to explore effective treatment strategies for patients who may have these resistant mutations. This approach seeks to enhance the precision of therapies and improve outcomes for patients facing drug-resistant cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with melanoma or other cancers who may be at risk of drug resistance due to genetic mutations.
Not a fit: Patients who do not have cancer or those whose cancers are not associated with drug resistance mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with drug-resistant cancers, potentially improving their chances of recovery.
How similar studies have performed: Other research has indicated that subclonal drug resistance mutations are prevalent in various cancers, suggesting that this approach could yield significant insights and advancements in treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Kwong, Lawrence — University of Tx Md Anderson Can Ctr
- Study coordinator: Kwong, Lawrence
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.